ALT Altimmune Inc

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Piper Sandler 2nd Annual Virtual Obesity Investor Day, being held on June 26, 2024, to discuss key takeaways from the American Diabetes Association’s (ADA) Scientific Sessions. Details on the fireside chat are as follows:

Title:	Piper Sandler Virtual Obesity Investor Day
Presenters:	Vipin Garg, Ph.D., Chief Executive OfficerScott Roberts, Ph.D., Chief Scientific Officer
Date/Time:	Wednesday, June 26, 2024 at 9:30 a.m. EDT

The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.

About AltimmuneAltimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter

Company Contact:Richard EisenstadtChief Financial OfficerPhone: 240-654-1450ir@altimmune.com

Investor Contacts:Lee RothBurns McClellanPhone: 646-382-3403lroth@burnsmc.com Julia WeilmanBurns McClellanPhone: 646-732-4443jweilman@burnsmc.com

Media Contact:Danielle CanteyInizio Evoke CommsPhone: 619-826-4657Danielle.cantey@inizioevoke.com